Cipher Pharmaceuticals Inc T.CPH

Buzz on the Bullboards: Quarterly reports and company mergers

[WolfOakville]

"After looking at the results, I feel the concerns I had two months ago coming out of their 2024 annuals were justified." Click for full review

[Jonathon Brown]

This week also marks the heart of quarterly earnings season, when companies disclose their financial and operational performance. read article.

[Alex1726]

Yes i agree, from a pespective of revenu's missing it would have been much more valuable if the counpond would have worked, but that's the way it is in clinical trials sometimes it fails. Let&

[drewmumaw]

I wouldn't call losing out on $50 million USD in potential revenue for MOB-015 in Canada "nothing". https://www.mobergpharma.com/partners/licensing

[Alex1726]

Not a huge one, they've lost $500k it's nothing.

[drewmumaw]

MOB-015 phase 3 failure was a huge gut punch.

[Possibleidiot01]

  Forwarded this email? Subscribe here for more

[drewmumaw]

And, based on the call this morning, several licensing deals for Natroba are in the works.

[Alex1726]

Craig Mull is a real good manager, someone that really works for shareholders. Natroba acquisition is almost paid off and a buy back is in place. Congratulation to you and your teams. 

[Possibleidiot01]

Cipher Pharma (CPH) • After years of looking for an acquisition, Cipher pulled the trigger and acquired the rights and the U.S. sales force of Natroba (head lice and scabies). The acquisition not only

[retiredcf]

Cipher Pharmaceuticals Inc. shares rose by more than 16 per cent this week after the company reported a big jump in both fourth-quarter revenue and adjusted EBITDA. After markets closed on Tuesday

[drewmumaw]

I was just speculating based on the recent stock price decline and comments on stagnant Natroba sales numbers I had read elsewhere. The annual results quelled my concerns. Two particularly positive

[prophetoffactz]

the Company also incurred $0.9 million of legal costs in Q4 2024 related to Cipher's claim that Sun Pharmaceuticals Industries, Inc. ("Sun") breached the supply and

[PressRelease]

(All figures are presented in U.S. Dollars)Generated $8.3 million in cash during Q4 2024Natroba™ revenue was $12.0 million for the 5 months of fiscal 2024 since acquisitionFull year adjusted EBITDA1 of $15.7 million, an increase of 23% over fiscal 2023Cash at December 31, 2024 was $17.8 million...read article.

[smush74]

as drewmumaw  posted this  has happened before back in 2014/2015 ran up to close to 20$ then crashing down to the 2$ range. Looks like the same thing all over. March 18th when they release

[retiredcf]

Is a pretty good indication that this stock is being played by the Market Makers. Either that, or there is suddenly considerable enthusiasm about the upcoming earnings (after the close on 18 March